Johnson & Johnson's second-quarter sales were US$25.31 billion, compared with estimates of US$25.04 billion; Adjusted earnings per share in the second quarter were $2.90
Johnson & Johnson's second-quarter sales were US$25.31 billion, compared with estimates of US$25.04 billion. Adjusted earnings per share in the second quarter were $2.90. Drug revenue in the second quarter was US$16.38 billion, compared with the estimate of US$16.12 billion. Johnson & Johnson expects full-year adjusted earnings per share of $11.60 to $11.75. Johnson & Johnson expects full-year sales of US$100.8 billion to US$101.4 billion, compared with market estimates of US$101.07 billion. Johnson & Johnson U.S. stocks rose slightly before the market opened.